The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоСтивен Хан <1%
Сара Бреннер <1%
Кайл Диамантис <1%
Нет объявления до 31 декабря <1%
$34,838 Объем
$34,838 Объем
Кайл Диамантис
<1%
Стивен Хан
1%
Бретт Жируар
<1%
Грейс Грэм
<1%
Сара Бреннер
1%
Нет объявления до 31 декабря
<1%
Стивен Хан <1%
Сара Бреннер <1%
Кайл Диамантис <1%
Нет объявления до 31 декабря <1%
$34,838 Объем
$34,838 Объем
Кайл Диамантис
<1%
Стивен Хан
1%
Бретт Жируар
<1%
Грейс Грэм
<1%
Сара Бреннер
1%
Нет объявления до 31 декабря
<1%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Открытие рынка: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено


Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы